Sanders K H, Beller K D, Kolassa N
Department of Pharmacology, Byk Gulden Pharmaceuticals, Konstanz, F.R.G.
J Cardiovasc Pharmacol. 1990;15 Suppl 7:S86-93.
This study investigated the effects of (-)-pindolol, a putative 5-HT1A receptor antagonist, upon the central hypotensive action of the antihypertensive drug urapidil and of the purported 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in cats. Chloralose/urethane-anesthetized cats were thoracotomized and artificially ventilated. Blood pressure was monitored in the iliac artery, and the drugs were injected into the vertebral artery. Urapidil (1-300 nmol/kg) or 8-OH-DPAT (0.01-1 nmol/kg) dose-dependently reduced blood pressure. (-)-Pindolol (30 and 100 nmol/kg) shifted the dose-response curves of both drugs significantly and in a similar manner to the right. Doses of urapidil of 30 nmol/kg or higher also reduced the elevation of blood pressure following the intravenous injection of the alpha 1-adrenoceptor agonist cirazoline whereas 8-OH-DPAT was ineffective. Yet, the hypotensive response to the directly acting vasodilator nitroglycerin remained unchanged after urapidil. The results support the hypothesis that the centrally mediated component of the antihypertensive action of urapidil is due to stimulation of 5-HT1A receptors in the brainstem. Peripheral alpha 1-adrenoceptor blockade comes into play with higher doses of the drug administered via the vertebral artery.
本研究调查了一种假定的5-羟色胺1A受体拮抗剂(-)-吲哚洛尔对降压药乌拉地尔以及所谓的5-羟色胺1A受体激动剂8-羟基-2-(二正丙基氨基)四氢萘(8-OH-DPAT)在猫体内的中枢性降压作用的影响。用氯醛糖/乌拉坦麻醉猫后进行开胸手术并实施人工通气。监测髂动脉血压,并将药物注入椎动脉。乌拉地尔(1-300 nmol/kg)或8-OH-DPAT(0.01-1 nmol/kg)呈剂量依赖性降低血压。(-)-吲哚洛尔(30和100 nmol/kg)以相似的方式使两种药物的剂量-反应曲线显著右移。30 nmol/kg或更高剂量的乌拉地尔也能降低静脉注射α1-肾上腺素受体激动剂可乐定后血压的升高,而8-OH-DPAT则无效。然而,乌拉地尔给药后对直接作用的血管扩张剂硝酸甘油产生的降压反应保持不变。这些结果支持以下假说:乌拉地尔降压作用的中枢介导成分是由于刺激了脑干中的5-羟色胺1A受体。通过椎动脉给药较高剂量药物时,外周α1-肾上腺素受体阻滞发挥作用。